Sign In
Buy HSDT
$1.51
-0.120 (-7.36%)
At Close: Jun 23, 2026
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
09:00am, Friday, 10'th May 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuro
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
10:15pm, Monday, 06'th May 2024
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
Why Is Helius Medical Technology (HSDT) Stock Up 47% Today?
08:12am, Friday, 03'rd May 2024
Helius Medical Technology (NASDAQ: HSDT ) stock is rocketing higher on Friday alongside heavy trading of the neurotechnology company's shares. This has more than 3.5 million shares of HSDT stock chan
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
09:05am, Wednesday, 24'th Apr 2024
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the
Helius Medical stock rallies 40%: explore why
07:55am, Wednesday, 03'rd Apr 2024
Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
07:05am, Wednesday, 03'rd Apr 2024
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually --
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
08:45pm, Thursday, 28'th Mar 2024
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 28'th Mar 2024
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company foc
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
07:05am, Friday, 15'th Mar 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neu
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
08:59am, Tuesday, 12'th Mar 2024
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
07:00am, Thursday, 07'th Mar 2024
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
07:00am, Monday, 04'th Mar 2024
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
07:00am, Tuesday, 06'th Feb 2024
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS�
